Sagimet Biosciences stock surges 30% on acne trial plans
Investing.com Gold reports: Sagimet Biosciences stock surges 30% on acne trial plans. Full body text was unavailable at ingest time, so this brief is based on headline context.
Investing.com Gold reports: Sagimet Biosciences stock surges 30% on acne trial plans. Full body text was unavailable at ingest time, so this brief is based on headline context.